Therefore, the safety and tolerability profile of retatrutide aligns with other incretin-primarily based therapies (hormones made by the intestine that assist regulate blood sugar concentrations). In vivo research, in individuals, implies that retatrutide activates and it is a complete agonist of each of the incretin receptors such as GIPR, GLP-